Innovative PK/PD approaches to improve dosing
09 July 2021
5. New antibacterial agents, PK/PD & Stewardship, 1-hour Mini Oral Flash
•
S11
•
09:30
>
10:30
•
Innovative PK/PD approaches to improve dosing
•
5. Antimicrobials & stewardship
09:30
•
3338
•
Imipenem population pharmacokinetics in neutropenic adults patients
>
M.
Matthieu
LAFAURIE (Paris)
09:35
•
3863
•
Model-informed translation of <em>in vitro</em> meropenem effects against <em>Pseudomonas aeruginosa</em> to diverse clinical situations
>
I.
Iris K.
MINICHMAYR (Uppsala)
09:40
•
387
•
Characterisation of nacubactam pharmacokinetics-pharmacodynamics (PK-PD) for efficacy in combination with cefepime against carbapenemase-producing Enterobacterales in a one compartment<em> in vitro </em>infection model
>
B.
Brian D.
VANSCOY (Schenectady, Ny)
09:45
•
1412
•
Population pharmacokinetic and the probability of target attainment of fosfomycin in healthy male volunteers
>
A.
Angela Elma
EDWINA (Rotterdam)
09:50
•
3607
•
Population pharmacokinetics of cefazolin in maternal and umbilical cord sera and target attainment in term neonates
>
O.
Omar
ELKAYAL (Leuven)
09:55
•
3352
•
Probability of target attainment of antibiotics in obese patients can conventional pharmacokinetic/pharmacodynamic targets adequately capture target-site penetration?
>
D.
David
BUSSE (Berlin)
10:00
•
1983
•
Amikacin in emergency surgery: how to dose it optimally?
>
S.
Sylvain
GOUTELLE (Lyon)
10:05
•
981
•
A semi-mechanistic model of the bactericidal activity of high-dose isoniazid against multidrug-resistant tuberculosis
>
K.
Kamunkhwala
GAUSI (Cape Town)
10:10
•
646
•
Influence of the clindamycin-administration route on the magnitude of clindamycin-rifampicin interaction: a prospective pharmacokinetic study
>
V.
Valérie
ZELLER (Paris)
10:15
•
INT5
•
Q&A/Discussion
|